All In Biotech

Drug Trial Radar · NCT04362007

A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma

A Phase I/II, Multicenter, Open-Label, Nonrandomized Study to Evaluate the Tolerability and Safety of ASTX660 and the Efficacy at the Recommended Dose of ASTX660 in Patients With Relapsed or Refractory T-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

8

Actual

Start

Jul 14, 2020

Primary completion

Nov 30, 2024

Study completion Nov 30, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1 (dose-escalation part): Investigate the tolerability and safety of ASTX660 in patients with r/r PTCL and r/r CTCL and determine the recommended dose (RD) for the Phase 2. Phase 1 (ATLL expansion part): Evaluate the safety of ASTX660 at RD in patients with r/r ATLL. Phase 2 : Evaluate the efficacy of ASTX660 at RD in patients with r/r PTCL.

Conditions

  • Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)

Interventions

  • ASTX660Drug

    Treatment of ASTX660 for r/r PTCL and r/r CTCL

  • ASTX660Drug

    Treatment of ASTX660 for r/r ATLL

  • ASTX660Drug

    Treatment of ASTX660 for r/r PTCL

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety (Phase 1 Dose-escalation Part) - Number of Subjects With Dose-limiting Toxicities (DLTs), AEs, Abnormal Clinical Laboratory Values or Physical Exam ResultsTime frame: 28 days (Day1 to Day29)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Yamagata University Hospital

    Yamagata, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.